Infliximab (Remicade, Inflectra, Renflexis, Avsola, Infliximab)_Non-oncology

Covers infliximab products (Remicade/Inflectra/Renflexis/Avsola) for specified FDA‑approved and compendial off‑label non‑oncology indications (e.g., Crohn’s, ulcerative colitis, RA, PsA, plaque psoriasis, ankylosing spondylitis, uveitis, GVHD, hidradenitis suppurativa, JIA, etc.) and excludes immunotherapy‑related hepatitis. Key requirements include indication‑specific age limits, specialist prescribing/consultation, documented prior therapy trials (e.g., RA: 3‑month trial of a biologic or csDMARD), documentation of diagnosis, dosing/infusion per policy, and reauthorization generally after the defined treatment period (commonly ≥6 months) with objective clinical response or symptom improvement.

"Immunotherapy-related toxicities associated with checkpoint inhibitor therapy"

Sign up to see full coverage criteria, indications, and limitations.